|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MAL |
Gene summary for MAL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MAL | Gene ID | 4118 |
| Gene name | mal, T cell differentiation protein | |
| Gene Alias | MVP17 | |
| Cytomap | 2q11.1 | |
| Gene Type | protein-coding | GO ID | GO:0001766 | UniProtAcc | A0A024RE19 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4118 | MAL | P23T-E | Human | Esophagus | ESCC | 4.29e-11 | 8.19e-01 | 0.108 |
| 4118 | MAL | P128T-E | Human | Esophagus | ESCC | 3.99e-07 | 9.11e-01 | 0.1241 |
| 4118 | MAL | S014 | Human | Liver | HCC | 1.15e-08 | 7.37e-01 | 0.2254 |
| 4118 | MAL | S015 | Human | Liver | HCC | 2.71e-07 | 8.24e-01 | 0.2375 |
| 4118 | MAL | S016 | Human | Liver | HCC | 7.18e-17 | 1.19e+00 | 0.2243 |
| 4118 | MAL | C43 | Human | Oral cavity | OSCC | 7.87e-03 | -1.70e-01 | 0.1704 |
| 4118 | MAL | LN22 | Human | Oral cavity | OSCC | 5.83e-06 | 2.19e+00 | 0.1733 |
| 4118 | MAL | SYSMH4 | Human | Oral cavity | OSCC | 4.35e-08 | 1.01e-01 | 0.1226 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00550921 | Stomach | WIM | sterol homeostasis | 8/426 | 97/18723 | 1.66e-03 | 2.15e-02 | 8 |
| GO:00714562 | Stomach | WIM | cellular response to hypoxia | 10/426 | 151/18723 | 2.43e-03 | 2.84e-02 | 10 |
| GO:00426322 | Stomach | SIM | cholesterol homeostasis | 14/708 | 96/18723 | 1.46e-05 | 4.95e-04 | 14 |
| GO:00550922 | Stomach | SIM | sterol homeostasis | 14/708 | 97/18723 | 1.65e-05 | 5.39e-04 | 14 |
| GO:00362935 | Stomach | SIM | response to decreased oxygen levels | 28/708 | 322/18723 | 3.96e-05 | 1.12e-03 | 28 |
| GO:00016665 | Stomach | SIM | response to hypoxia | 26/708 | 307/18723 | 1.14e-04 | 2.70e-03 | 26 |
| GO:00704825 | Stomach | SIM | response to oxygen levels | 28/708 | 347/18723 | 1.45e-04 | 3.25e-03 | 28 |
| GO:00550881 | Stomach | SIM | lipid homeostasis | 16/708 | 167/18723 | 6.11e-04 | 9.21e-03 | 16 |
| GO:00362944 | Stomach | SIM | cellular response to decreased oxygen levels | 14/708 | 161/18723 | 3.24e-03 | 3.08e-02 | 14 |
| GO:007048227 | Thyroid | HT | response to oxygen levels | 50/1272 | 347/18723 | 3.61e-07 | 1.65e-05 | 50 |
| GO:003629327 | Thyroid | HT | response to decreased oxygen levels | 46/1272 | 322/18723 | 1.34e-06 | 5.14e-05 | 46 |
| GO:000166627 | Thyroid | HT | response to hypoxia | 44/1272 | 307/18723 | 2.07e-06 | 7.53e-05 | 44 |
| GO:007145324 | Thyroid | HT | cellular response to oxygen levels | 26/1272 | 177/18723 | 1.62e-04 | 2.43e-03 | 26 |
| GO:003629424 | Thyroid | HT | cellular response to decreased oxygen levels | 23/1272 | 161/18723 | 5.63e-04 | 6.62e-03 | 23 |
| GO:007145618 | Thyroid | HT | cellular response to hypoxia | 21/1272 | 151/18723 | 1.36e-03 | 1.29e-02 | 21 |
| GO:004505610 | Thyroid | HT | transcytosis | 6/1272 | 21/18723 | 2.17e-03 | 1.88e-02 | 6 |
| GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
| GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
| GO:0006417113 | Thyroid | PTC | regulation of translation | 236/5968 | 468/18723 | 2.70e-17 | 2.52e-15 | 236 |
| GO:0042273113 | Thyroid | PTC | ribosomal large subunit biogenesis | 57/5968 | 72/18723 | 1.79e-16 | 1.51e-14 | 57 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MAL | SNV | Missense_Mutation | c.88N>C | p.Glu30Gln | p.E30Q | P21145 | protein_coding | deleterious(0.01) | possibly_damaging(0.881) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MAL | SNV | Missense_Mutation | rs745729561 | c.139C>T | p.Pro47Ser | p.P47S | P21145 | protein_coding | tolerated(0.1) | probably_damaging(0.988) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MAL | SNV | Missense_Mutation | rs775300945 | c.428N>T | p.Ala143Val | p.A143V | P21145 | protein_coding | tolerated(0.05) | benign(0.426) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MAL | SNV | Missense_Mutation | novel | c.254N>C | p.Val85Ala | p.V85A | P21145 | protein_coding | tolerated(0.47) | benign(0.243) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| MAL | SNV | Missense_Mutation | c.359G>T | p.Arg120Met | p.R120M | P21145 | protein_coding | deleterious(0.03) | benign(0.369) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MAL | SNV | Missense_Mutation | c.127T>A | p.Ser43Thr | p.S43T | P21145 | protein_coding | deleterious(0.02) | possibly_damaging(0.744) | TCGA-CM-6679-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| MAL | SNV | Missense_Mutation | rs749751444 | c.335N>T | p.Thr112Met | p.T112M | P21145 | protein_coding | tolerated(0.22) | benign(0.022) | TCGA-D5-6924-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MAL | SNV | Missense_Mutation | novel | c.145N>G | p.Pro49Ala | p.P49A | P21145 | protein_coding | tolerated(0.16) | benign(0.039) | TCGA-DM-A28F-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| MAL | SNV | Missense_Mutation | rs775300945 | c.428N>T | p.Ala143Val | p.A143V | P21145 | protein_coding | tolerated(0.05) | benign(0.426) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MAL | SNV | Missense_Mutation | novel | c.89A>G | p.Glu30Gly | p.E30G | P21145 | protein_coding | deleterious(0) | probably_damaging(0.913) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |